"I love Beckley Psytech | Home"

2022-07-12 17:57:18

Our Mission Our Research Our Story Our Team Our Investors Contact Us Our News Our Mission Our Research Our Story Our Team Our Investors Contact Us Our News Our Mission Our Research Working with Patients in Mind Learn More Our Mission Beckley Psytech is dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Sign up to our newsletter to keep up to date with our mission Our Story Our Research Beckley Psytech’s primary aim is to help patients in need by developing psychedelic medicines that offer significant improvements over currently available neuropsychiatric treatments. To that end, we are building a pipeline of psychedelic compounds with distinct clinical attributes for mental and neurological diseases. Our development programs will focus on offering innovation and clear differentiation in the marketplace over existing treatmentoptions. Our R&D platform can be divided into three distinct though interrelatedcategories: 01 “1st Generation” Psychedelic Medicine: Progressing innovative formulations and applications of well-characterised psychedelic agents such as psilocybin and othercompounds 02 “2nd Generation” Psychedelic Medicine: Developing known but under-researched psychedelic agents with potential clinical and patient access advantages over the first wave of psychedelicmedicines 03 “3rd Generation” Psychedelic Medicine: Designing New Chemical Entities (NCEs) that improve upon existing psychedelics by providing better clinical and cost-efficacyoutcomes Our Team Our Story For our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, psychedelic medicines have been a lifelong and inter-generationalvocation. Amanda has dedicated over 50 years to the scientific exploration of psychedelics in the belief that modern science can be used to understand, validate, and optimise the healing potential of psychedelic medicines. In 1998 Amanda set up (and continues to run) the Beckley Foundation, a non-profit NGO focused on evidence-based drug policy reform and scientific research into psychedelicmedicines. Over the last 20 years the Beckley Foundation has become a world-famous pioneer in psychedelic research. Amanda has been dubbed “the hidden hand” behind the renaissance in psychedelic science, featured on the Guardian’s list of the Bravest Men and Women in the History of Science, and has personally co-authored over 50 peer-reviewed scientific publications on the subject, many with ground-breakingresults. Highlights of the Beckley Foundation’s work include: 1998 Study on psychedelics and cerebral circulation 2007 First Ethics Committee approval of LSD study since prohibition 2009 Beckley-Imperial Psychedelic Research Program 2011 Global public letter for Drug Policy Reform 2012 First ever brain imaging study on psilocybin 2014 First ever brain imaging study on LSD 2014 Psilocybin Tobacco Addiction Study 2016 Psilocybin Treatment Resistant Depression 2017 Ayahuasca Neurogenesis study 2018 LSD Microdosing study Beckley Psytech was created to build upon the Foundation’s work by developing safe and effective psychedelic medicines available to patients in need and integrating these treatments into mainstream medicalpractice. Beckley Psytech has a close strategic partnership with the Beckley Foundation and, in addition to its own pipeline, will provide financial and technical support to develop the Foundation’s most promising research. The company is committed to improving the lives of patients in need and will donate a share of future revenues to fund the non-profit work of the Foundation. Highlights of the Beckley Foundation’s work include: 1998 Study on psychedelics and cerebral circulation 2007 First Ethics Committee approval of LSD study since prohibition 2009 Beckley-Imperial Psychedelic Research Program 2011 Global public letter for Drug Policy Reform 2012 First ever brain imaging study on psilocybin 2014 First ever brain imaging study on LSD 2014 Psilocybin Tobacco Addiction Study 2016 Psilocybin Treatment Resistant Depression 2017 Ayahuasca Neurogenesis study 2018 LSD Microdosing study Contact Us Contact Us General enquiries — [email protected] Media enquiries — [email protected] Subscribe to our newsletter Keep up to date with the latest news and information Back to top Privacy Policy Cookie Policy © Beckley Psytech Ltd. 2020